Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

rcp 106 > 106 final > Flashcards

106 final Flashcards

(126 cards)

Start Studying
1
Q

chemical name of a drug

A

actual chemical structure of a drug (xyz2y)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

generic name of a drug

A

a name assigned by the USAN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

official name of a drug

A

-(generic + USP)
- becomes fully approved by the FDA, then listed in the USP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Trade/Brand Name of a drug

A

-brand name given by the manufacturer
-this name is “owned” by the manufacturer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Calculate the therapeutic index (TI)

A

TI= LD50/ED50
-LD = lethal dose
-ED= effective dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

low TI

A

-unsafe, drugs are safer as TI increases
-No completely safe drug out there

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Concomitance

A

2 drugs given at the same time to produce an effect that is the sum of the effect that each produces on its own. This is pure addition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Synergism

A

occurs when drugs with similar actions are given concomitantly and produce an effect that is greater than the sum of the effect that each produces on its own.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Potentiation

A

drugs with unlike actions are given concomitantly and produce an effect that is greater than the sum that each produces on its own

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Antagonism

A

occurs when drugs act concomitantly in a way that one drug causes the actions of the other drug to be reduced

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Median lethal dose (LD)

A

The dose which kills half of test subjects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Median Effective Dose (ED50)

A

The dose at which half of
tested subjects show the desired therapeutic response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

three main uses for aerosols

A

-humidification of dry inspired gases using bland aerosols
-mobilization and clearance of respiratory secretions, including sputum induction
-delivery of aerosolized drugs to the respiratory tract

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

2.5 micrometers

A

useful to treat lower respiratory tract (large airways to periphery) (bronchodilators)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

disadvantages of aerosol drug delivery

A

-many variables affect dose delivered to airways
-cannot measure effectiveness of dosage delivery
-can be difficult for patients to self-administer
-MDs, NPs, and RNs unfamiliar with device use and administration
-many device types lead to confusion among patients and practitioners

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

advantages of aerosol drug delivery

A

-doses are smaller than doses fir systemic treatment
-drug delivery is targeted to respiratory system for local effect
-systemic side effects are fewer and less severe than oral/parenteral therapy
-painless and convient
-lungs provide a portal to the body for systemic effects( pain control)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

disadvantages of MDIs

A

-complex hand-breathing coordination required for efficacy
-fixed drug concentrations and dosages
-not easy to know when canister is empty
-reactions to propellants
-high volume loss without use of spacer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

advantages of MDIs

A

-portable, light and compact
-efficient drug delivery
-short treatment time
-easy to use
-more than 100 doses are available
-fine particle sizes are available in HFA form
-not easily contaminated
-no prep drug needed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

MDI

A

small, pressurized canisters for oral or nasal inhalation of aerosol drugs and contain multiple doses of accurately metered drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

DPI

A

-breath-actuated inhaler where drug is in powder form
-can be unit dose (individually wrapped capsules or multiple doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

disadvantages of DPIs

A

-limited range of drug availability
-patients not always aware of dose inhaled
-moderate to high inspiratory flow rates necessary
-high oropharyngeal impaction and deposition
-single-dose devices need to be loaded every time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

advantages of DPIs

A

-small and portable
-short preparation and administration times
-breath-actuated, no need for hand-breathing coordination
-no inspiratory hold needed
-no CFC propellants (environmentally friendly)
-built- in dose counter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

valve holding chamber

A

-an extension device
-high-velocity large particles > slower- velocity small particle
-reduces oropharyngeal deposition, amount of drug swallowed, local oropharygneal side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

disadvantages of valve holding chamber

A

-large and inconvenient
-additional expense
-possible source of bacterial contamination
-patient error prone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
SVN
type of aerosol generator that converts liquid drug solutions or suspensions into aerosol
26
disadvantages of SVN
-not easily portable (mobile) -requires assembly
27
advantages of SVN
-longer treatment time = better deposition
28
lbs to kgs
1kg= 2.2 lbs
29
convert % solution to mg/mL
-multiple by 10 or move the decimal point one place to the right -2% = 20 mg/mL -0.3% = 3 mg/mL
30
express ratios as % solutions
-divide the first part by the second part and multiply by 100 -1:500= (1/500) x 100 = 0.2%
31
convert mL to mg
mg= (mg/mL) x mL
32
convert mg to mL
mL= mg/ (mg/mL)
33
ANS branches
-parasympathetic -sympathetic
34
ANs keypoints
-drugs either mimic the neurotransmitter (NT) to produce the usual action or block the NT to inhibit it -ANS is generally efferent-> impulses travel from brain/spinal cord out to body
35
Parasympathetic branch
-NT is acetylcholine (Ach)
36
Ach
-located at neuromuscular junction (NJ) and ganglia -terminated by the enzyme cholinesterase
37
Parasympathetic
- drugs that mimic/allow/increase Ach transmission -parasympathomimetic= cholinergic= muscarinic
38
Parasympatholytic
-drugs that block the transmission of Ach to achieve opposite effects (for us, bronchodilation) -anticholinergic= antimuscarinic= muscarinic antagonists
39
Parasympathetic regulation
-craniosacral (from cranial nerves to sacral nerves) -essential of life -discrete, finely regulated system (i.e. digestion, bladder discharge, bronchial secretions) -overstimulation= SLUD syndrome
40
SLUD Syndrome
-Salivation -Lacrimation (tears) -Urination -Defecation
41
cholinergic responses to Ach (effects) on cardiopulmonary system
-decreased heart rate -lower blood pressure -bronchoconstriction (bronchial smooth muscle) -increased mucus secretion in airways
42
Meds of the parasympathetic branch
-parasympatholytic -antimuscarinic -antinicotinic -anticholinergic -muscarinic -antagonists
43
MOA of parasympathetic
M3 receptor = affects airway smooth muscle
44
sympathetic location
-thoracic nerves - lumber nerves
45
sympathetic branch
-also called adrenergic
46
Sympathetic (adrenergic) effects
NT release from sympathetic nerves release catecholamines (norepinephrine and epinephrine) from adrenal medulla and stimulate adrenergic receptors throughout the body
47
Sympathetic effects on the cardiopulmonary system include:
-Increased heart rate -Increased contractile force -Increased blood pressure -Bronchodilation -Probable increased secretions from mucous glands in airway
48
Sympathetic receptor types:
-Alpha -Beta
49
Alpha receptors
-excitatory effects -vasoconstriction (upper airway) -Alpha -1 = peripheral blood vessels -meds= racemic epi
50
Beta receptors
-relaxing effects (inhibit) -Beta -1 = not important -Beta -2 = smooth muscle (bronchial and cardiac) dilation
51
bronchospasm
narrowing of bronchial airways caused by smooth muscle contraction
52
adrenergic bronchodilators clinical indications:
-used for the treatment of reversible airway obstruction in asthma and COPD -agents that stimulate sympathetic nerve fibers = bronchodilate
53
Adrenergic bronchodilators 2 groups:
- SABA (short-acting beta-2 agonists) -LABA (long-acting beta-2 agonists)
54
SABA
-albuterol 2.5 mg/ 0.5mL -levalbuterol= Xopenex= 0.63mg/2mL -relief of acute reversible airflow obstruction -'rescue' agents or 'relievers'
55
LABA
-'erol' -salmeterol= serevent -formoterol= performist (SVN)/ foradil (DPI) -aformoterol= brovana -olodaterol= striverdi maintenance of bronchodilation and control of bronchospasm -'controllers' -not for rescue therapy
56
special consideration : racemic epinephrine
-svn -Q 2 hrs - 11.25% in 0.5 mL -strong alpha -1 vasoconstrictor -alpha agonist
57
Indications for racemic epi
-post-extubation stridor -croup -epiglottitis -upper airway bleeding (endoscopy)
58
all sympathetic (adrenergic) bronchodilators:
are either catecholamines or derivatives of catecholamines
59
catecholamines found in the body:
-dopamine -epinephrine -norepinephrine
60
catecholamine structure
-benzine ring -two hydroxyl groups -amine side chain
61
keyhole theory of beta-2 agonists:
the longer the side chain, the greater the beta-2 effect
62
catecholamines =
sympathomimetic amines that mimic epinephrine
63
side effects of catecholamines:
-tachycardia -increased blood pressure -palpitations -bronchial smooth muscle relaxation -CNS stimulation
64
catecholamines derivatives:
- man-made -modified nucleus -not found in the body -resorcinols -saligenins (albuterol)
65
prodrug
-Bitolterol -drug that is inactive until the body converts it (hydrolysis) to the active drug
66
SABA/LABA side effects
-muscle tremor -cardiac effects (tachycardia, palpitations, increased blood pressure) -headache -insomnia -bronchospasm -hypokalemia
67
anticholinergic bronchodilator
-agent that blocks Ach transmission at parasympathetic nerve fibers, which allows for relaxation of airway smooth muscle - blocks Ach at parasympathetic post-ganglionic effector cell receptors -helps to reduce respiratory secretions
68
anticholinergic=
parasympatholytic= antimuscarinic= muscarinic antagonists
69
indications for anticholinergic bronchodilators
-maintenance therapy for COPD -may be indicated for some with asthma -often used in combination with other bronchodilators (beta-2 agonists) and inhaled corticosteriods (ICS)
70
anticholinergic agents 2 groups:
-'ium' -SAMA -LAMA
71
inhaled corticosteriods (ICS)
- oral inhalation and intranasal delivery agents that produce in anti-inflammatory response -reduce airway thickening cause by inflammatory process -recommended for maintenance therapy for COPD
72
corticosteriods=
glucocorticosteriods= glucocorticiods= steriods
73
causes of airway inflammation:
-infection (airway, systemic, ARDS) -allergic and non-allergic stimulation of asthma -direct or indirect trauma - inhalation of noxious or toxic substances
74
antigens
-natural defense mechanism (immune system) is to neutralize, destroy, and eliminate foreign materials -stimulate both the immune and inflammatory processes
75
common antigens:
-animal dander -dust mites -mold -pollen -smoke -bacteria
76
mediated by
inflammatory cells (mast cells, eosinophils, T lymphocytes , macrophages)
77
Airway inflammation
-microvascular leakage -airway wall swelling -mucus secretion -which cause - wheezing - shortness of breath -chest tightness - cough -treatments with ICS reduce the basal level of airway inflammation, airway hyperresponsiveness, and exacerbations
78
systemic corticosteroids
-given orally or by IV -'relievers' for patients in severe acute asthma exacerbations (for COPD) -reduce inflammation associated with asthma more quickly than ICS -meds include: prednisone, methlyprednisone (Medrol and Solumedrol), and dexamethasone (Decadron) -more side effects than ICS
79
inhaled corticosteroids
- given via SVN, DPI, MDI -used for maintenance of COPD -most often work best when combined with LABA -fewer side effects than systemic steroids - must rinse mouth out after use to prevent oral thrush
80
nonsteroidal antiasthma agents:
-medications that have an anti-inflammatory effect through mechanisms different from corticosteroids -used for prophylactic management (control) of mild persistent asthma requiring anti-inflammatory drug therapy
81
Mast cell mediator:
-i.e. histamine, heparin, leukotrienes -causes degranulation of mast cells
82
the effects of degranulation:
-bronchospasm -mucus production - airway edema
83
the goal of all asthma/allergy medication is:
to stop/limit mast cell degranulation
84
relievers of asthma:
-SABAs (albuterol, levalbuterol) -systemic corticosteroids (prednisone, dexamethasone) -SAMAs (atrovent)
85
controllers of asthma
-ICS - oral corticosteroids -cromolyn sodium (mast cell stabilizer) -LABAs -Leukotriene modifiers -monoclonal antibodies
86
Leukotriene modifiers (antileukotrienes)
-attach to and block the receptor for leukotrienes -Zileuton (Zyflo) -controller -Zafirlukast (Accolate) - controller -Monetlukast (Singulair) - controller (especially good for exercise-induced asthma)
87
monoclonal antibodies
-Omalizumab (Xolair) -used to treat uncontrolled moderate - to - severe asthma in ages 12 and up
88
mucus
-secretion from surface goblet cells and submucosal glands -composed of water, proteins, and mucins
89
phlegm
purulent material in the airways
90
sputum
expectorated phlegm; respiratory tract; oropharyngeal; and nasopharyngeal secretions, bacteria, and products of inflammation
91
mucoactive agents
- any medication or drug that has an effect on mucus secretion -also called mucolytics/ mucus controllers
92
mucolytic agents:
-medication that degrades polymers in secretions (break down mucin, DNA, and actin in sputum)
93
mucociliary transport:
-how well cilia moves mucus along the respiratory tract and how easy it is for patients to cough mucus out -is slowed by certain disease processes and substances that cause airway damage -give med aerosols and CPT (chest physiotherapy) to aid
94
mucociliary transport:
-COPD -CF (Cystic Fibrosis) -Endotracheal suctioning -airway trauma -tobacco smoke -atmospheric pollutants ( Sulfur dioxide, Nitrogen dioxide, Ozone, Allergens)
95
mucociliary system:
-protects the lungs from inhaled debris -contains enzymes that give it antimicrobial properties that help prevent infection -warms and humidifies inspired gases -prevents excessive loss of heat and moisture from airways
96
N-Acteylcysteine (Mucomyst)
-comes in 10% and 20% solution -smells like rotten egg -ordered as last resort for copious sputum production -not proven beneficial -can cause bronchospasm
97
Pulmozyme (Dornase Alfa)
-indicated ONLY for clearance of purulent secretions in cystic fibrosis (CF) -reduces viscosity of sputum -breaks down DNA polymers in sputum -2.5 mg in 2.5 mL refrigerated vial
98
Hypertonic saline
-also called hyperosmolar saline or hypersal -7% saline used for CF -3% saline used for infant and ped bronchiolitis -irritates and hydrates the airway to promote cough and loosening of secretions
99
Antiinfective Agents
nebulized aerosols for pulmonary infections associated with CF, pneumonia, RSV, etc.
100
Pentamidine (Nebupent)
-Antiinfective agent -indicated for prevention of PJP/PCP in high-risk HIV-infected patients -antifungal -delivered Respirgard II nebulizer
101
Tobramycin (Tobi)
-Antiinfective -indicated for management/control of chronic Pseudomonas aeurginosa infection in CF -must pretreat with bronchodilator (Albuterol) and use separate nebulizer only for Tobi
102
Aztreonam (Cayston)
-Antiinfective -indicated to improve pulmonary symptoms in pts with CF and active Pseudomonas aeruginosa infection -must pretreat with bronchodilator (albuterol)
103
Diuretics:
-drugs that promote urine production by reducing extracellular fluid volume to decrease blood pressure and/or to rid the body of excess fluid -affects the metabolic acid-base balance
104
water loss from diuretics can cause:
acid-base imbalances liek metabolic alkalosis (pH is directly proportional to bicarbonate (HCO3)(fluid)
105
diuretic indications:
-CHF -pulmonary edema -acute respiratory distress syndrome (ARDS) -fluid build up from trauma -acute/chronic renal failure
106
Furosemide (Lasix)
-loop diuretics -"high ceiling" diuretic -fast acting (15-20 minutes)
107
Neuromuscular blocking agents (NMBA) =
Skeletal Muscle Relaxants= paralytics
108
neuromuscular blockers:
-NMBAs prevent body movement by weakening or paralyzing muscles -this effect is produced by interfering with the neurotransmitter Ach at the neuromuscular junction
109
clinical uses of NMBAs:
-to facilitate endotracheal intubation -to obtain muscle relaxation during surgery -to enhance patient-ventilator synchrony -to paralyze pts who must remain immobile (trauma)
110
NMBA cause:
muscle paralysis without affecting consciousness or the perception of pain
111
NMBA either:
depolarize the presynaptic and postsynaptic membrane receptors or compete with Ach for binding of the Ach receptors at the NJ site
112
2 types of NMBAs;
-depolarizing -nondepolarizing
113
Succinylocholine
-depolarizing agent (only one) -ultra short action and duration -cannot be reversed -primarily used just prior to intubation -many severe side effects (not used as much as it used to be) -subsequent doses have limited effectiveness
114
nondepolarizing agents:
-'ium' -Pancuronium (Pavulon) -Rocuronium (Zemuron) -Vecuronium (Norcuron) -can be reversed by cholinesterase inhibitor Neostigmine
115
Sedatives
-Propofol (Diprivan) -Lorazepam (Ativan) -Midazolam (Versed)
116
Analgesics (pain control)
-Fentanyl -Hydromorphone (Dilaudid) -Morphine
117
Order given:
Sedatives > NMBAs > Analgesics
118
Inhaled Nitric Oxide (iNO)
-pulmonary vasodilator - approved for pulmonary vascular relaxation and is used to treat persistent pulmonary hypertension in newborns (PPHN) -used in conjunction with ventilatory support -PPHN diagnosed by cardiac echocardiogram and pre- and post- ductal oxygen saturation differences - very short half-life (5 seconds)
119
Epoprostenol
- pulmonary vasodilator - brand name Flolan (injection) and Veletri (inhalation) - not indicated for newborns
120
surfactants:
-used in premature infants who have decreased levels of pulmonary surfactant -acts as a lubricant to decrease pulmonary surface tension in the alveoli, which aids in ease of breathing
121
exogenous surfactant:
- manmade -decrease surface alveolar surface tension, which aids in alveolar inflation and helps prevent atelectasis, thereby improving overall breathing -made of 85-90% lipids and around 10% protein
122
Poractant alfa
-Curosurf -porcine (made from pig lung extract)
123
Beractant
-Survanta -Bovine ( made from minced cow lung extract)
124
Calfactant
-Infrasurf -Bovine (made from chloroform-methanol extract of fluid lavaged from calf lung)
125
surfactant risk factors and side effects:
-airway occlusion (clogs the ETT) -oxygen desaturation (from clogged ETT or oversaturation of alveoli) -bradycardia -overoxygenation (High PaO2) -overventilation -apnea -pulmonary hemmorrhage
126
Surfactants administered through:
via endotracheal tubes directly into the lungs

rcp 106 (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions